in the absence of a submission from the holder of the marketing authorisation:
lenacapavir (Sunlenca®) is not recommended for use within NHSScotland.
Indications under review:
Film-coated tablets: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection.
Solution for injection: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in these indications. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice238KB (PDF)
Medicine details
- Medicine name:
- lenacapavir (Sunlenca)
- SMC ID:
- SMC2691
- Indication:
Film-coated tablets: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection.
Solution for injection: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 July 2024